Literature DB >> 15231646

Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function.

Naohide Isaka1, Timothy P Padera, Jeroen Hagendoorn, Dai Fukumura, Rakesh K Jain.   

Abstract

Vascular endothelial growth factor (VEGF)-C is known to induce hyperplasia in normal murine lymphatics and in peritumor lymphatics. Here, we examine the function of these hyperplastic peritumor lymphatics. Microlymphangiography of B16F10 melanomas growing in the murine dorsal skinfold chamber showed that the number of functional, draining lymphatics in the peritumor tissue of VEGF-C-overexpressing tumors was significantly greater than that in mock-transduced tumors (9.5 +/- 1.0 versus 6.3 +/- 0.4; n = 6; P < 0.05). Forty percent of functional lymphatics associated with VEGF-C-overexpressing tumors contained proliferating lymphatic endothelial cells. Surprisingly, these new, functional lymphatic vessels displayed a retrograde draining pattern, which indicates possible dysfunction of the intraluminal valves of these vessels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231646     DOI: 10.1158/0008-5472.CAN-04-0752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.

Authors:  Shan Liao; Jieqiong Liu; Peichun Lin; Tony Shi; Rakesh K Jain; Lei Xu
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

2.  Notch leads lymphatics and links them to blood vessels.

Authors:  Shan Liao; Timothy P Padera; Rakesh K Jain
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09       Impact factor: 8.311

3.  Non-invasive MR assessment of macroscopic and microscopic vascular abnormalities in the rectal tumour-surrounding mesorectum.

Authors:  Ewelina Kluza; Jean-Paul J E Kleijnen; Milou H Martens; Dorit Rennspiess; Monique Maas; Cécile R L P N Jeukens; Robert G Riedl; Axel zur Hausen; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

4.  Impaired lymphatic contraction associated with immunosuppression.

Authors:  Shan Liao; Gang Cheng; David A Conner; Yuhui Huang; Raju S Kucherlapati; Lance L Munn; Nancy H Ruddle; Rakesh K Jain; Dai Fukumura; Timothy P Padera
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 5.  Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?

Authors:  Sunny Y Wong; Richard O Hynes
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

6.  Biomaterial guides for lymphatic endothelial cell alignment and migration.

Authors:  Echoe M Bouta; Connor W McCarthy; Alexander Keim; Han Bing Wang; Ryan J Gilbert; Jeremy Goldman
Journal:  Acta Biomater       Date:  2010-10-23       Impact factor: 8.947

7.  Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells.

Authors:  Gregory M Nelson; Timothy P Padera; Igor Garkavtsev; Toshi Shioda; Rakesh K Jain
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

8.  Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability.

Authors:  Myunghwan Choi; Taeyun Ku; Kyuha Chong; Jonghee Yoon; Chulhee Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

9.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22

10.  Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.

Authors:  Johanna Tuomela; Maija Valta; Jani Seppänen; Kati Tarkkonen; H Kalervo Väänänen; Pirkko Härkönen
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.